Canada Markets open in 12 mins
  • S&P/TSX

    20,099.81
    +400.71 (+2.03%)
     
  • S&P 500

    4,023.89
    +93.81 (+2.39%)
     
  • DOW

    32,196.66
    +466.36 (+1.47%)
     
  • CAD/USD

    0.7740
    -0.0007 (-0.0929%)
     
  • CRUDE OIL

    110.21
    -0.28 (-0.25%)
     
  • BTC-CAD

    38,713.41
    -699.61 (-1.78%)
     
  • CMC Crypto 200

    671.51
    -9.60 (-1.41%)
     
  • GOLD FUTURES

    1,807.10
    -1.10 (-0.06%)
     
  • RUSSELL 2000

    1,792.67
    +53.29 (+3.06%)
     
  • 10-Yr Bond

    2.9090
    -0.0260 (-0.89%)
     
  • NASDAQ futures

    12,354.25
    -28.50 (-0.23%)
     
  • VOLATILITY

    29.07
    -2.70 (-8.50%)
     
  • FTSE

    7,437.88
    +19.73 (+0.27%)
     
  • NIKKEI 225

    26,547.05
    +119.40 (+0.45%)
     
  • CAD/EUR

    0.7419
    -0.0017 (-0.23%)
     

Charles River Laboratories to Present at J.P. Morgan Healthcare Conference

  • Oops!
    Something went wrong.
    Please try again later.
·1 min read
In this article:
  • Oops!
    Something went wrong.
    Please try again later.

WILMINGTON, Mass., January 06, 2022--(BUSINESS WIRE)--Charles River Laboratories International, Inc. (NYSE: CRL) announced today that it will virtually present at the 40th Annual J.P. Morgan Healthcare Conference on Tuesday, January 11th, at 10:30 a.m. ET. Management will present an overview of Charles River’s strategic focus, business developments, and recent trends.

A live webcast of the presentation will be available through a link that will be posted on the Investor Relations section of the Charles River website at ir.criver.com. A webcast replay will be accessible through the same website after the presentation and will remain available for approximately two weeks.

About Charles River

Charles River provides essential products and services to help pharmaceutical and biotechnology companies, government agencies and leading academic institutions around the globe accelerate their research and drug development efforts. Our dedicated employees are focused on providing clients with exactly what they need to improve and expedite the discovery, early-stage development and safe manufacture of new therapies for the patients who need them. To learn more about our unique portfolio and breadth of services, visit www.criver.com.

View source version on businesswire.com: https://www.businesswire.com/news/home/20220106005052/en/

Contacts

Investor Relations Contact:
Todd Spencer
Corporate Vice President, Investor Relations
781.222.6455
todd.spencer@crl.com

Our goal is to create a safe and engaging place for users to connect over interests and passions. In order to improve our community experience, we are temporarily suspending article commenting